Health · Healthcare & Policy · 1 hr ago
Brazil’s Anvisa weighs limits on clinics using compounded weight-loss drugs
Brazil’s health regulator, Anvisa, is set to consider new rules for compounded weight-loss drugs on Wednesday.
The proposal would stop compounding pharmacies from supplying these medicines to clinics and other third parties for stock, patient injections or resale.
It would also bar pharmacies from building large stocks in advance and from advertising the products to drive prescriptions or sales.
Patients could still take an individual prescription directly to a pharmacy, if a doctor decides a custom formula is needed.
The debate follows a joint statement by Anvisa and federal police in May that said they had found volumes of compounded doses inconsistent with the rules and signs of complex organized crime.
The proposal aims to limit how these products are supplied and promoted, while the discussion comes amid pressure for wider access to obesity medicines.
Anvisa’s board is due to analyze the proposal next, but the sources do not say when a final decision would take effect.
Brazil’s Anvisa is considering rules that would prevent clinics from supplying or administering compounded weight-loss drugs.
The proposal is scheduled for review on Wednesday, November 25.
It would bar compounded products from being supplied to clinics and other third parties for stock, patient administration or resale.
The draft also proposes limits on advance production and marketing of compounded weight-loss drugs.
Anvisa’s debate comes amid calls for wider access to obesity medicines and concerns about the safety and scale of compounding.
- Who
- Brazil’s National Health Surveillance Agency, Anvisa, is considering the proposal.
- What
- The proposal would restrict clinics from supplying or administering compounded weight-loss drugs.
- When
- The proposal is scheduled for review on Wednesday, November 25; the article was published on November 22, 2026.
- Where
- Brazil.
- Why
- Anvisa’s technical staff view compounding as intended for customized products in exceptional cases, while authorities have reported volumes they say are incompatible with the rules.
Anvisa proposal’s supporters
Supporters of wider access to compounded medicines
Use by clinics
Anvisa proposal’s supporters
The proposal would bar supplying compounded products to clinics for stock, patient administration or resale.
Supporters of wider access to compounded medicines
Wider access to obesity medicines has prompted calls to use compounded products.
Compounding
Anvisa proposal’s supporters
Compounded medicines should be made for individualized needs and exceptional cases, according to the proposal’s rationale.
Supporters of wider access to compounded medicines
Health Minister Alexandre Padilha said compounding pharmacies can operate legitimately if they meet criteria, including providing customized doses.
Restrictions
Anvisa proposal’s supporters
The proposal would restrict advance production and marketing of compounded products.
Supporters of wider access to compounded medicines
Consumers and political actors have pressed for greater access to obesity medicines.
Anvisa and the Federal Police issued a joint note reporting compounded-dose volumes they said were incompatible with the rules.
Health Minister Alexandre Padilha told Folha that the debate had been suspended to organize discussion.
A court allowed Urupês to temporarily resume applications of compounded tirzepatide.
Anvisa’s board is scheduled to review the proposal.
- Review date
- Wednesday, November 25
- Proposal author
- Anvisa director Thiago Campos
- Proposed restriction
- No supply to clinics, medical offices, care facilities or other third parties for stock, administration or resale
- Medicine types
- GLP-1 and GIP agonists or co-agonists
- Urupês location
- About 420 km from São Paulo
- Local medicine
- Compounded tirzepatide
1 source
What people are saying
organize the debate
offering customized, individualized doses, which sometimes the medical professional wants but the industry does not produce